CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 293 enrolled
Drug / intervention
Observational Studyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02966145
NCT02966145N/ACompleted
CompareCT.gov

The Four-Repeat Tauopathy Neuroimaging Initiative

University of California, San Francisco·observational·Posted Nov 17, 2016·Updated Apr 13, 2025

In Brief

An observational study evaluating Observational Study for Corticobasal Degeneration (CBD) and 5 related conditions. Completed, enrolled 293 participants across 8 sites in 2 countries.

Detailed Summary

The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCorticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
CountriesCanada, United States
CollaboratorsNational Institutes of Health (NIH), National Institute on Aging (NIA)

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 17, 2016
Enrollment StartJan 1, 2016
Primary CompletionFeb 28, 2024
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 9.6 years ago

Interventions

Observational Studyother